The drugmaker is also widening the crackdown by calling on social platforms and other digital players to help stop illegal sales.
Zocdoc’s new Gemini integration lets users find and schedule care in one place, turning genAI into a patient acquisition channel.
Snap wants pharma’s ad dollars, with a new format that keeps Rx ads cleaner and compliant, though potential FDA disclosure changes could undercut its value.
Cancer patients turn to peers for practical tips and clinicians for treatment decisions, creating an opportunity for pharma brands to partner with creators and advocacy groups to complement clinical guidance.
AI tools built by healthcare providers must capitalize on their trust edge over general-purpose chatbots to drive adoption.
The executive order also targets combined MMR shots, widening the divide between federal policy and medical guidance.
A new FDA proposal would require food brands to defend ingredients “generally recognized as safe” and make nutrition info more publicly available.
Novo Nordisk adds AWS to its AI roster. Deep-pocketed drugmakers can test multiple AI partners, an advantage smaller rivals may lack.
Taylor Farms’ recall reaches major grocers, widening the potential fallout from the recent produce scare.
In today’s podcast episode, we discuss what’s driving the current surge in interest in health wearables, which wearable health metrics are reliable enough for clinical decision-making, the leading devices on the market, and how AI is helping transform them into comprehensive digital health hubs. Join Senior Director of Podcasts and host Marcus Johnson, along with Senior Analysts Rajiv Leventhal and Beth Snyder Bulik, as they explore these topics. Listen wherever you get your podcasts, or watch on YouTube or Spotify.
Generic “AI-generated” tags aren’t enough to help TikTok users spot deepfake doctors or fabricated medical claims.
Easier scheduling, transportation, and virtual care can get patients to the doctor, but they need clearer guidance on when to seek screenings or telehealth.
Food and beverage brands can tailor protein benefits to GLP-1 users, athletes, and others with higher protein needs.
New Mexico’s $942M order tests whether courts can require product changes alongside financial penalties.
As brands strive to create lasting connections with interested consumers, Playtex Sport is counting on active creators to reach those who will care the most and drive sales to retailers.
Hims & Hers adds doctor-backed AI guidance for women’s weight loss members, underscoring that AI convenience and care quality are emerging as critical competitive advantages beyond GLP-1 access.
Gen Z turns to YouTube, while millennials to Facebook—underscoring the need for social content that helps consumers parse GLP-1 options.
The FDA decision reinforces the need for clinical evidence, but approval alone won't drive adoption.
Novo's Wegovy pill gains failed to offset declines in injectable sales. Investors continue to favor companies like Lilly with broader drug pipelines despite a positive outlook for GLP-1 pills.
CPG brands such as P&G are betting consumers won't cut back on wellness spending, favoring premium supplements like Thorne’s over cheaper alternatives.